INTERVENTION 1:	Intervention	0
Cohort 1	Intervention	1
Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks	Intervention	2
day	UO:0000033	36-39
x	LABO:0000148	48-49
x	LABO:0000148	89-90
x	LABO:0000148	281-282
x	LABO:0000148	343-344
x	LABO:0000148	420-421
carboplatin	CHEBI:31355	105-116
auc	BAO:0002120	120-123
doxorubicin	CHEBI:28748,BAO:0000639	279-290
cyclophosphamide	CHEBI:4026	305-321
surgery	OAE:0000067	365-372
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)	Intervention	3
x	LABO:0000148	27-28
x	LABO:0000148	68-69
carboplatin	CHEBI:31355	84-95
auc	BAO:0002120	99-102
week	UO:0000034	61-65
week	UO:0000034	73-77
week	UO:0000034	163-167
week	UO:0000034	221-225
INTERVENTION 2:	Intervention	4
Cohort 2	Intervention	5
Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10) Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks	Intervention	6
x	LABO:0000148	4-5
x	LABO:0000148	58-59
x	LABO:0000148	99-100
x	LABO:0000148	325-326
x	LABO:0000148	387-388
x	LABO:0000148	457-458
x	LABO:0000148	518-519
carboplatin	CHEBI:31355	115-126
auc	BAO:0002120	130-133
week	UO:0000034	92-96
week	UO:0000034	104-108
week	UO:0000034	194-198
week	UO:0000034	252-256
week	UO:0000034	381-385
week	UO:0000034	451-455
week	UO:0000034	462-466
week	UO:0000034	512-516
week	UO:0000034	523-527
surgery	OAE:0000067	272-279
doxorubicin	CHEBI:28748,BAO:0000639	323-334
cyclophosphamide	CHEBI:4026	349-365
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)	Intervention	7
x	LABO:0000148	27-28
x	LABO:0000148	68-69
carboplatin	CHEBI:31355	84-95
auc	BAO:0002120	99-102
week	UO:0000034	61-65
week	UO:0000034	73-77
week	UO:0000034	163-167
week	UO:0000034	221-225
Eligibility criteria	Eligibility	0
Inclusion criteria:	Eligibility	1
Histologically documented adenocarcinoma of the breast	Eligibility	2
adenocarcinoma	DOID:299	26-40
breast	UBERON:0000310	48-54
ANC > 1000 cells	Eligibility	3
Female; age > 18	Eligibility	4
female	PATO:0000383	0-6
age	PATO:0000011	8-11
Zubrod PS 0-1	Eligibility	5
Platelets > 100,000	Eligibility	6
Stage IIA-IIIB disease	Eligibility	7
disease	DOID:4,OGMS:0000031	15-22
Total bilirubin < 1.5 ULN	Eligibility	8
No evidence of any metastatic disease	Eligibility	9
disease	DOID:4,OGMS:0000031	30-37
Serum Creatinine < 1.5 gm/dl	Eligibility	10
creatinine	CHEBI:16737	6-16
No prior systemic therapy for breast cancer or Creat Cl > 30 ml/min	Eligibility	11
breast cancer	DOID:1612	30-43
cl	BAO:0002759	53-55
Not pregnant or lactating	Eligibility	12
Serum ALT < 2.0 ULN	Eligibility	13
ER, PR and HER2 status required	Eligibility	14
LVEF (MUGA/echo WNL)	Eligibility	15
No baseline > 2 neuropathy	Eligibility	16
neuropathy	DOID:870	16-26
Urine protein: creat ratio < 1.0	Eligibility	17
urine	UBERON:0001088	0-5
protein	CHEBI:36080,BAO:0000175	6-13
ratio	UO:0000190	21-26
HER2-negative - either IHC 0-1+ or FISH ratio < 2.0	Eligibility	18
ratio	UO:0000190	40-45
Hemoglobin > 9 gm/dl	Eligibility	19
hemoglobin	CHEBI:35143	0-10
(FISH testing is required for all HER2 2-3+ tumors by IHC)	Eligibility	20
Exclusion criteria:	Eligibility	21
No Histologically documented adenocarcinoma of the breast	Eligibility	22
adenocarcinoma	DOID:299	29-43
breast	UBERON:0000310	51-57
No-ANC > 1000 cells	Eligibility	23
Female; age < 18	Eligibility	24
female	PATO:0000383	0-6
age	PATO:0000011	8-11
Zubrod PS > 0-1	Eligibility	25
Platelets < 100,000	Eligibility	26
Stage IV disease	Eligibility	27
disease	DOID:4,OGMS:0000031	9-16
Total bilirubin > 1.5 ULN	Eligibility	28
metastatic disease	Eligibility	29
disease	DOID:4,OGMS:0000031	11-18
Serum Creatinine > 1.5 gm/dl	Eligibility	30
creatinine	CHEBI:16737	6-16
prior systemic therapy for breast cancer or Creat Cl > 30 ml/min	Eligibility	31
breast cancer	DOID:1612	27-40
cl	BAO:0002759	50-52
pregnant or lactating	Eligibility	32
Serum ALT > 2.0 ULN baseline > 2 neuropathy	Eligibility	33
neuropathy	DOID:870	33-43
Urine protein: creat ratio >1.0	Eligibility	34
urine	UBERON:0001088	0-5
protein	CHEBI:36080,BAO:0000175	6-13
ratio	UO:0000190	21-26
HER2-positive	Eligibility	35
Hemoglobin < 9 gm/dl	Eligibility	36
hemoglobin	CHEBI:35143	0-10
Outcome Measurement:	Results	0
Pathological Complete Response Rates at Surgery	Results	1
surgery	OAE:0000067	40-47
[Not Specified]	Results	2
Time frame: at surgery approximately 5 months after initial treatment	Results	3
time	PATO:0000165	0-4
surgery	OAE:0000067	15-22
Results 1:	Results	4
Arm/Group Title: Cohort 1	Results	5
Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks	Results	6
day	UO:0000033	59-62
x	LABO:0000148	71-72
x	LABO:0000148	112-113
x	LABO:0000148	304-305
x	LABO:0000148	366-367
x	LABO:0000148	443-444
carboplatin	CHEBI:31355	128-139
auc	BAO:0002120	143-146
doxorubicin	CHEBI:28748,BAO:0000639	302-313
cyclophosphamide	CHEBI:4026	328-344
surgery	OAE:0000067	388-395
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)	Results	7
x	LABO:0000148	27-28
x	LABO:0000148	68-69
carboplatin	CHEBI:31355	84-95
auc	BAO:0002120	99-102
week	UO:0000034	61-65
week	UO:0000034	73-77
week	UO:0000034	163-167
week	UO:0000034	221-225
Overall Number of Participants Analyzed: 28	Results	8
Measure Type: Number	Results	9
Unit of Measure: participants  16	Results	10
Results 2:	Results	11
Arm/Group Title: Cohort 2	Results	12
Arm/Group Description: Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10) Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks	Results	13
x	LABO:0000148	27-28
x	LABO:0000148	81-82
x	LABO:0000148	122-123
x	LABO:0000148	348-349
x	LABO:0000148	410-411
x	LABO:0000148	480-481
x	LABO:0000148	541-542
carboplatin	CHEBI:31355	138-149
auc	BAO:0002120	153-156
week	UO:0000034	115-119
week	UO:0000034	127-131
week	UO:0000034	217-221
week	UO:0000034	275-279
week	UO:0000034	404-408
week	UO:0000034	474-478
week	UO:0000034	485-489
week	UO:0000034	535-539
week	UO:0000034	546-550
surgery	OAE:0000067	295-302
doxorubicin	CHEBI:28748,BAO:0000639	346-357
cyclophosphamide	CHEBI:4026	372-388
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)	Results	14
x	LABO:0000148	27-28
x	LABO:0000148	68-69
carboplatin	CHEBI:31355	84-95
auc	BAO:0002120	99-102
week	UO:0000034	61-65
week	UO:0000034	73-77
week	UO:0000034	163-167
week	UO:0000034	221-225
Overall Number of Participants Analyzed: 27	Results	15
Measure Type: Number	Results	16
Unit of Measure: participants  2	Results	17
Adverse Events 1:	Adverse Events	0
Total: 5/28 (17.86%)	Adverse Events	1
gr 3 Nausea, gr 3 vomiting  1/28 (3.57%)	Adverse Events	2
nausea	HP:0002018	5-11
vomiting	HP:0002013	18-26
gr 3 nausea, gr 2 infection with noraml ANC, gr 2 HGB, gr 1 glucose  1/28 (3.57%)	Adverse Events	3
nausea	HP:0002018	5-11
glucose	CHEBI:4167,BAO:0000924	60-67
gr 2 non-cardiac chest pain, gr 2 anemia  1/28 (3.57%)	Adverse Events	4
chest pain	HP:0100749	17-27
anemia	HP:0001903,DOID:2355	34-40
gr 3 infection (normal ANC) (cellulitis & pain in buttock - RT infection), gr 1 epistaxis  1/28 (3.57%)	Adverse Events	5
cellulitis	HP:0100658,DOID:3488	29-39
pain	HP:0012531	42-46
epistaxis	HP:0000421	80-89
Adverse Events 2:	Adverse Events	6
Total: 8/27 (29.63%)	Adverse Events	7
gr 3 Nausea, gr 3 vomiting  0/27 (0.00%)	Adverse Events	8
nausea	HP:0002018	5-11
vomiting	HP:0002013	18-26
gr 3 nausea, gr 2 infection with noraml ANC, gr 2 HGB, gr 1 glucose  0/27 (0.00%)	Adverse Events	9
nausea	HP:0002018	5-11
glucose	CHEBI:4167,BAO:0000924	60-67
gr 2 non-cardiac chest pain, gr 2 anemia  0/27 (0.00%)	Adverse Events	10
chest pain	HP:0100749	17-27
anemia	HP:0001903,DOID:2355	34-40
gr 3 infection (normal ANC) (cellulitis & pain in buttock - RT infection), gr 1 epistaxis  0/27 (0.00%)	Adverse Events	11
cellulitis	HP:0100658,DOID:3488	29-39
pain	HP:0012531	42-46
epistaxis	HP:0000421	80-89
